ArticleInfection and immunity2004
Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.Clinical and vaccine immunology : CVI · 2009Trial
- Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Clinical and vaccine immunology : CVI · 2006Trial
- Article
- Cross-reactivity with Brazilian strains ofTherapeutic advances in vaccines and immunotherapy · 2019Article
- Impact of meningococcal group B OMV vaccines, beyond their brief.Human vaccines & immunotherapeutics · 2018Article
- Article
- Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.Human vaccines & immunotherapeutics · 2016Review
- Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.The Pediatric infectious disease journal · 2015Article
- Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.Infection and immunity · 2014Article
- fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.Vaccine · 2013Article
- Neisseria lactamica antigens complexed with a novel cationic adjuvant.Human vaccines & immunotherapeutics · 2013Article
- Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.Infection and immunity · 2012Article
- A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.Vaccine · 2010Article
- Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2010Article
- Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.Vaccine · 2009Review
- Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.Clinical and vaccine immunology : CVI · 2009Article
- Evidence of a functional B-cell immunodeficiency in adults who experience serogroup C meningococcal disease.Clinical and vaccine immunology : CVI · 2009Article
- Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Infection and immunity · 2009Article
- Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.Infection and immunity · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The hallmark of immunity to meningococcal disease is a bactericidal titer in serum of > or =1:4 measured with human complement, but this threshold titer may underestimate the extent of protection. We used the infant rat model of meningococcal bacteremia to measure group C passive protective activity in serum samples from 91 unimmunized adults living in California. A total of 35 sera (38.5%) had passive protective activity. Sera with complement-mediated bactericidal titers of > or =1:4 were 3.4-fold more likely to confer protection (89%) than nonbactericidal sera (26%; P < 0.0001). Thus, bactericidal titers of > or =1:4 are a marker of protection, but this threshold lacks sensitivity for predicting protective activity. We investigated the 73 sera with bactericidal titers of <1:4 to determine the basis of protective activity. The 19 sera with protective activity had a higher geometric mean group C anticapsular antibody concentration (0.72 microg/ml) than the 54 sera that lacked protective activity (0.16 microg/ml; P < 0.001). Thus, protective activity in the absence of bactericidal activity was associated with higher concentrations of anticapsular antibodies, but not all sera with anticapsular antibodies conferred protection. Of 18 nonbactericidal sera with anticapsular antibody concentrations between 0.31 and 0.99 microg/ml, the 11 sera that conferred protection had a higher mean antibody avidity constant (21.9 nM(-1)) than the 7 nonprotective sera (14.6 nM(-1); P < 0.03). Thus, in sera with titers of <1:4, protective activity is associated with higher-avidity group C anticapsular antibodies, which are present in concentrations insufficient to elicit complement-mediated bacteriolysis in vitro but sufficient to confer protection in an in vivo bacteremia model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.